相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial
C. Weinstein et al.
ANNALS OF ONCOLOGY (2016)
Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin
Hideaki Yahata et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2016)
Comparison between 5-day aprepitant and single-dose fosaprepitant meglumine for preventing nausea and vomiting induced by cisplatin-based chemotherapy
Yosuke Ando et al.
SUPPORTIVE CARE IN CANCER (2016)
Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial
Masakazu Abe et al.
SUPPORTIVE CARE IN CANCER (2016)
A Randomized Controlled Pilot Study Comparing the Impact of Aprepitant and Fosaprepitant on Chemotherapy Induced Nausea and Vomiting in Patients Treated for Gynecologic Cancer
John P. Micha et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2016)
Optimized selection of three major EGFR-TKIs in advanced EGFR-positive non-small cell lung cancer: a network meta-analysis
Yaxiong Zhang et al.
ONCOTARGET (2016)
A review of olanzapine as an antiemetic in chemotherapy-induced nausea and vomiting and in palliative care patients
C. Fonte et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): A multicentre, randomised, controlled phase 3 trial
Junichi Nishimura et al.
EUROPEAN JOURNAL OF CANCER (2015)
Efficacy of palonosetron and 1-day dexamethasone in moderately emetogenic chemotherapy compared with fosaprepitant, granisetron, and dexamethasone: a prospective randomized crossover study
Hiromitsu Kitayama et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2015)
Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial
Lee S. Schwartzberg et al.
LANCET ONCOLOGY (2015)
Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials
Bernardo L. Rapoport et al.
LANCET ONCOLOGY (2015)
Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC)
Bernardo Rapoport et al.
SUPPORTIVE CARE IN CANCER (2015)
Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study
P. J. Hesketh et al.
ANNALS OF ONCOLOGY (2014)
A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy
R. J. Gralla et al.
ANNALS OF ONCOLOGY (2014)
A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy
M. Aapro et al.
ANNALS OF ONCOLOGY (2014)
Aprepitant, Granisetron, and Dexamethasone for Prevention of Chemotherapy-Induced Nausea and Vomiting After High-Dose Melphalan in Autologous Transplantation for Multiple Myeloma: Results of a Randomized, Placebo-Controlled Phase III Trial
Thomas Schmitt et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy
Yasuhiro Ito et al.
LUNG CANCER (2014)
Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial
Zhihuang Hu et al.
SUPPORTIVE CARE IN CANCER (2014)
Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial
H. Saito et al.
ANNALS OF ONCOLOGY (2013)
A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy
M. Tanioka et al.
BRITISH JOURNAL OF CANCER (2013)
ADDIS: A decision support system for evidence-based medicine
Gert van Valkenhoef et al.
DECISION SUPPORT SYSTEMS (2013)
Management of Chemotherapy-Induced Nausea and Vomiting Focus on Newer Agents and New Uses for Older Agents
Rudolph M. Navari
DRUGS (2013)
Pharmacological mechanisms of 5-HT3 and tachykinin NK1 receptor antagonism to prevent chemotherapy-induced nausea and vomiting
Camilo Rojas et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2012)
Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study
Paul J. Hesketh et al.
SUPPORTIVE CARE IN CANCER (2012)
Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol-EASE
Steven Grunberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
Ethan Basch et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin
Toshiaki Takahashi et al.
CANCER SCIENCE (2010)
Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study
Bernardo L. Rapoport et al.
SUPPORTIVE CARE IN CANCER (2010)
Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting (Reprinted)
F. Roila et al.
ANNALS OF ONCOLOGY (2009)
A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy
Winnie Yeo et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Phase 2 Trial Results With the Novel Neurokinin-1 Receptor Antagonist Casopitant in Combination With Ondansetron and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Patients Receiving Moderately Emetogenic Chemotherapy
Wichit Arpornwirat et al.
CANCER (2009)
Phase III Trial of Casopitant, a Novel Neurokinin-1 Receptor Antagonist, for the Prevention of Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy
Jorn Herrstedt et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis
Andrea Cipriani et al.
LANCET (2009)
Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial
Steven M. Grunberg et al.
LANCET ONCOLOGY (2009)
Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial
Mitsue Saito et al.
LANCET ONCOLOGY (2009)
Aprepitant in Adolescent Patients for Prevention of Chemotherapy-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Tolerability
Lia Gore et al.
PEDIATRIC BLOOD & CANCER (2009)
Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting
Jon D. Herrington et al.
CANCER (2008)
Evaluation of networks of randomized trials
Georgia Salanti et al.
STATISTICAL METHODS IN MEDICAL RESEARCH (2008)
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy
M. S. Aapro et al.
ANNALS OF ONCOLOGY (2006)
Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment
H. J. Schmoll et al.
ANNALS OF ONCOLOGY (2006)
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy
DG Warr et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide
F Roila
JOURNAL OF CLINICAL ONCOLOGY (2004)
Palonosetron:: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis
SM Grunberg et al.
EXPERT OPINION ON PHARMACOTHERAPY (2003)
Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist -: Results of a phase III, single-dose trial versus dolasetron
P Eisenberg et al.
CANCER (2003)
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - The Aprepitant Protocol 052 Study Group
PJ Hesketh et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy
R de Wit et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron
R Gralla et al.
ANNALS OF ONCOLOGY (2003)
Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting - Results from a randomized, double-blind, placebo-controlled trial in Latin America
S Poli-Bigelli et al.
CANCER (2003)
Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting
SP Chawla et al.
CANCER (2003)
Quantifying heterogeneity in a meta-analysis
JPT Higgins et al.
STATISTICS IN MEDICINE (2002)
Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: A meta-analysis of randomized evidence
JPA Ioannidis et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
分享论文
